Clinical Trials Logo

Cognitive Deficits clinical trials

View clinical trials related to Cognitive Deficits.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02746523 Terminated - Clinical trials for Proprioceptive Disorders

Effects of Multiple Concussions in Retired NHL Players

NHL
Start date: March 2016
Phase: N/A
Study type: Observational

To investigate long term affects of multiple concussions on the cognition, balance, proprioception, and biomarkers in retired National Hockey League players

NCT ID: NCT02266121 Terminated - Clinical trials for Relapsing Remitting Multiple Sclerosis

Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis

MScog-tDCS
Start date: October 2014
Phase: N/A
Study type: Interventional

Noninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments to enhance their cognitive aptitudes.

NCT ID: NCT01813955 Terminated - Schizophrenia Clinical Trials

Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia

Start date: June 2011
Phase: Phase 0
Study type: Interventional

Phosphodiesterase (PDE) inhibitors represent a new group of potential antipsychotic compounds currently under development. One of these is papaverine, an inhibitor of the PDE 10 family. The class of PDE10 inhibitors have been reported as possible candidates in the treatment of schizophrenia, and may prove an attractive antipsychotic alternative due to the many side-effects of the currently available antipsychotics. It has been proposed from preclinical studies that PDE10 inhibitors have the potential to reduce cognitive deficits in schizophrenia and these findings need to be confirmed in a human population, in view of the fact that no other currently registered drug posses these unique properties. The currently proposed project is designed to investigate whether the PDE10 inhibitor Papaverine indeed have the capacity to reduce cognitive deficits in schizophrenia patients. In order to accomplish this effect, Papaverine will be investigated in schizophrenia, with regards to symptomatology, hemodynamic, neurocognition and early information-processing.